Cell & Gene Therapy Bioanalytical Testing Services Market Size, Share & Industry Report, 2026 - 2034
REPORT DETAILS
Cell & Gene Therapy Bioanalytical Testing Services Market Summary and Key Insights
The cell & gene therapy bioanalytical testing services market size was valued at USD 579.30 million in 2025.The market is anticipated to grow from USD 620.75 million in 2026 to USD 1091.86 million by 2034, exhibiting a CAGR of 7.30% during 2026–2034.
Market Statistics
Key Takeaways
• Asia Pacific held the largest share of 43.0% in the global cell & gene therapy bioanalytical testing services market in 2025. The dominance is attributed to the increasing prevalence of chronic health conditions across the world.
• China led the Asia Pacific market with 42.0% revenue share in 2025. The market growth in China is fueled by increasing focus on R&D and surging demand for effective healthcare and specialty care.
• The market in Europe is expected to register a substantial CAGR of 7.2% during the forecast period. Support from government and nongovernment organizations for advancements in cell and gene therapies propels the regional market growth.
• The bioavailability and bioequivalence studies segment is expected to exhibit a significant CAGR of 34.0% during the forecast period. This is due to the growing drug development activities and increasing imposition of stringent biopharmaceutical regulations.
• The cell therapy segment held the largest revenue share of 7.3%% in 2025. The increasing development of cell therapies is propelling the demand for bioanalytical testing services.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Increasing clinical trials for cell and gene therapies propel demand for specialized bioanalytical testing services across development stages.
- Stringent regulatory requirements for safety, potency, and biodistribution testing drive greater outsourcing to experienced bioanalytical service providers.
- High testing complexity and the shortage of skilled bioanalytical professionals limit service capacity and raise operational costs.
- Expanding investments in personalized medicine and advanced therapy pipelines would create lucrative opportunities for specialized testing laboratories.
- Integration of automation, AI-enabled data analysis, and high-throughput analytical platforms would become a key emerging market trend in the coming years.
Cell & Gene Therapy Bioanalytical Testing Services in Simple Terms
Cell and gene therapy bioanalytical tests refer to the laboratory services aimed at determining the safety and effectiveness of new therapy products. Bioanalytical services are utilized by the pharmaceutical industry in order to analyze the working mechanisms of treatments, ensure the compliance with regulations, and support the developments of the therapies.
Market Overview
The rising prevalence of chronic diseases, such as cancer, which lack permanent cures, is significantly driving the demand for advanced cell and gene therapies, as well as intensifying research in this domain. Furthermore, the implementation of increasingly stringent government safety guidelines is compelling researchers to develop high-efficacy, safer cell and gene therapies. These dynamics are collectively contributing to the robust growth of the global cell and gene therapy bioanalytical testing services market.
For instance, in April 2024, the Biologics Evaluation and Research Center of the Food and Drug Administration launched two new guidance drafts for the safe testing of cell and gene therapy products. First draft includes products developed from human allogeneic cells, and the other contains cell and gene therapies produced by animal- and human-derived materials.
Source: Polaris Market Research Analysis
To Understand More About this Research:Download Sample Report
How Cell & Gene Therapy Bioanalytical Testing Services Work?
- Sample Collection: The biological samples, which include blood, tissue, plasma, or serum, are obtained from preclinical trials or clinical trial patients.
- Laboratory Testing: Highly advanced testing methodologies are used to recognize the therapeutic cells, gene vectors, biomarkers, and other biological agents.
- Biomarker Testing: Biomarkers are tested for the analysis of the effects and safety of the treatment, along with the potency and biological activity.
- Pharmacokinetic Testing: Specialists test the treatment's effect on absorption, distribution, persistence, metabolism, and elimination of the treatment within the body.
- Data Interpretation: Data from the tests is analyzed for evaluating the efficiency of the treatment and potential concerns of safety.
- Regulatory Reporting: Data validation is performed for report generation to comply with the needs of regulatory agencies and to facilitate product filings.
- Clinical Trial Validation: The results of the bioanalytical process are used to validate clinical trials.
Ongoing developments of new cell and gene therapies are creating favorable market conditions for bioanalytical testing services. For instance, as per the study published in Nature Biotechnology, the approvals of cell and gene therapies reached an all-time high in 2023. This includes five gene therapies, CRISPR-Cas9-edited therapies, and one disease modifying Alzheimer's drug. Thus the rising development in the new cell therapies is further driving the market growth over the forecast period.
Real-World Applications of Cell & Gene Therapy Bioanalytical Testing Services
- Testing of cancer immunotherapy: Its role is to analyze the safety, effectiveness, and immune response of CAR-T cell therapy, T cell receptor therapy (TCR), and other cellular therapeutic products in the development stage.
- Gene therapy for rare genetic disorders: During this study, both the gene expression and the functionality of the vectors are analyzed for the purposes of developing therapies for diseases with an inherited mechanism.
- Cell-Based Regenerative Medicine Trials: The study of the cells for the identification of their effectiveness and for evaluation of safety of or cellular products.
- Vaccine Development Support Studies: This method helps evaluate the immune reactivity and effectiveness of the vaccine candidates based on viral vectors and nucleotides.
Growth Drivers
Rising Investments in Cell and Gene Therapy Developments Drive the Market Growth
The rising global demand for cell and gene therapies is driving substantial investments in development activities, thereby increasing the need for bioanalytical testing solutions in this sector. For instance, the New York administration announced a USD 98 million investment in cell and gene therapy manufacturing to support the design and production of cancer treatments and other life-saving technologies. This trend is expected to significantly boost the demand for bioanalytical testing services during the forecast period. Furthermore, the growing demand for effective healthcare and specialty care is fueling innovation in cell and gene therapies, prompting market players to expand into bioanalytical testing services. For instance, in April 2024, Walgreens introduced Walgreens Specialty Pharmacy, a comprehensive service expanding care for patients with complex conditions while enhancing profitability through strategic partnerships. This investment is made to advance its specialty pharmacy offerings, including gene and cell therapy services. These developments are contributing to the growth of the cell and gene therapy bioanalytical testing services market.
Growing Development of Cell and Gene Therapies Drives Market Growth
The increasing awareness and benefits of cell and gene therapies and the limited side effects of these therapies are fostering healthcare research initiatives across the world. Ongoing research collaborations to enhance cell and gene therapy capabilities create demand for bioanalytical testing services. For instance, In April 2025, Xcell Biosciences entered a research collaboration with Labcorp to produce Xcellbio’s AVATAR incubator system for the R&D of cell therapy. In turn, LabCorp announced a rise in strategic investments in Xcellbio. The rising prevalence of deadly diseases is forcing researchers to conduct cell and gene research. In a 2025 study published in Cell Stem Cell, researchers discovered a new treatment method for polycystic kidney disease through gene editing technologies. Also, they developed a new drug, glycoside, to reduce or remove the effect of defective genes.
Growing Demand for Personalized Medicine
The rising need for personalized medicine propelled the use of bioanalytical testing services related to cell and gene therapy. Personalized medicine involves medical treatments that address the specific genetics and molecular nature of each patient. Precision medicine requires sophisticated analytical techniques to assess the effects of such therapies and their potency, efficacy, and biomarker profile. Such testing allows developers to determine the efficiency of the therapy and improve the dosing regime. Thus, pharmaceutical companies, biotechnology firms, and contract research organizations increasingly invest in advanced analytical technologies to support the development of customized therapies. It is driving the growth of the bioanalytical testing services market.
Restraining Factors
Stringent Regulations Hinders the Market Growth
The huge costs of designing and producing cell and gene therapies, the lower chance of attaining high-performing therapeutics, and growing government stringent regulations are negatively impacting the market. The limited availability of skilled professionals in the biopharmaceutical sector and the need for effective healthcare infrastructure also hinder the cell & gene therapy bioanalytical testing services market growth.
Source: Polaris Market Research Analysis
Cell & Gene Therapy Bioanalytical Testing Services Market Report Segmentation
The cell & gene therapy bioanalytical testing services market is segmented on the basis of test type, product type, stage of development, indication, and region.
| By Test Type | By Product Type | By Stage of Development | By Indication | By Region |
|
|
|
|
|
Source: Polaris Market Research Analysis
By Test Type Analysis
Bioavailability & Bioequivalence Studies Segment to Witness Highest Growth Rate in Cell & Gene Therapy Bioanalytical Testing Services Market
The cell & gene therapy bioanalytical testing services market for the bioavailability and bioequivalence segment is expected to grow at the fastest pace owing to the rising drug development activities. Bioequivalence studies are used to monitor human body reactions and the functioning of the treatment. The rising stringent biopharmaceutical regulations are promoting the use of bioavailability and bioequivalence studies to evaluate the safety and efficiency of therapies for treating human diseases.
By Product Type Analysis
Cell Therapy Segment Accounted for Largest Share in Cell & Gene Therapy Bioanalytical Testing Services Market
The cell therapy segment accounted for the largest revenue share in 2023 and is likely to retain its market dominance during the forecast period. The rising development of cell therapies is positively impacting the demand for bioanalytical testing services. Moreover, the FDA has accelerated approvals for cell therapies, reflecting a rapidly evolving landscape driven by advancements in treating complex diseases. For instance, in March 2024, the US FDA announced the approval of Breyanzi, an initial cell therapy developed by the Breyanzi, for the treatment of small lymphocytic lymphoma in adults. This surge in approvals highlights the growing importance of cell therapy in modern healthcare, thereby contributing to the market growth.
Source: Polaris Market Research Analysis
Advanced Technologies in Cell & Gene Therapy Bioanalytical Testing
| Technology | Application in Bioanalytical Testing | Key Benefit |
| LC-MS/MS (Liquid Chromatography–Mass Spectrometry) | Quantifies therapeutic molecules, metabolites, and biomarkers with high precision during pharmacokinetic and bioavailability studies. | High sensitivity, accuracy, and reliable quantitative analysis. |
| Flow Cytometry Analysis | Identifies, characterizes, and quantifies immune cells, stem cells, and engineered cell populations such as CAR-T cells. | Rapid multi-parameter cellular analysis and precise cell characterization. |
| Next-Generation Sequencing (NGS) Support | Detects genetic variants, transgene integration, vector sequences, and gene expression profiles for gene therapies. | Comprehensive genomic analysis with high throughput and accuracy. |
| Biomarker-Based Testing Platforms | Measures protein, genetic, and molecular biomarkers to evaluate therapy response, efficacy, and safety. | Enables personalized treatment assessment and early response monitoring. |
| Automated Laboratory Analytics Systems | Automates sample preparation, testing workflows, data processing, and quality control in bioanalytical laboratories. | Improves throughput, reduces manual errors, and enhances reproducibility. |
Cell & Gene Therapy Bioanalytical Testing Services Market Regional Insights
Asia Pacific Held Largest Share of Global Cell & Gene Therapy Bioanalytical Testing Services Market in 2025
Asia Pacific accounted for the dominant share in the cell & gene therapy bioanalytical testing services market due to the rising prevalence of chronic health conditions, including cancer and neurological and genetic disorders, enabling companies to propel their gene and cell therapy research. Countries such as China, India, and Japan are recording a rise in number of cancer cases. For instance, according to the ICMR-NCRP, cancer cases are expected to reach 1.57 million by 2025 from 1.46 million in 2022. Thus, the rising number of cancer patients will further fuel research initiatives in cell and gene therapies, which in turn increase the demand for cell & gene therapy bioanalytical testing services in the Asia Pacific.
Europe is expected to register a significant CAGR in the cell & gene therapy bioanalytical testing services market during the forecast period. Government and nongovernment organizations are supporting advancements in cell and gene therapies by providing funds to companies engaged in R&D activities. For instance, in March 2023, the UK government announced the Life Sciences Innovative Manufacturing Fund (LSIMF) for biotech companies. Pharmaron and Touchlight received USD 190 million and USD 17.7 million, respectively, for cell and gene therapy development and production.
Regional Future Trends in the Cell & Gene Therapy Bioanalytical Testing Services Market
| Region | Future Trend |
| North America |
|
| Europe |
|
| Asia Pacific |
|
| Latin America |
|
| Middle East & Africa |
|
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Regulatory Landscape
| Regulatory Aspect | Impact on the Cell & Gene Therapy Bioanalytical Testing Services Market |
| FDA and EMA Guidelines Drive Testing Standards | Regulatory guidance from the U.S. FDA and the European Medicines Agency (EMA) establishes standardized requirements for bioanalytical testing, ensuring the safety, efficacy, and quality of cell and gene therapies. |
| Strict Validation Requirements for Gene Therapies | Developers must validate analytical methods for potency, identity, purity, biodistribution, immunogenicity, vector shedding, and stability to support clinical development and product approvals. |
| Increasing Global Harmonization of Clinical Testing Rules | Greater alignment of international regulatory frameworks is simplifying multinational clinical trials and promoting standardized bioanalytical testing practices across global markets. |
| Growing Demand for GLP-Compliant Testing Services | Pharmaceutical and biotechnology companies are increasingly partnering with GLP-compliant laboratories to ensure data integrity, regulatory compliance, and acceptance by global health authorities. |
Source: Polaris Market Research Analysis
Key Market Players and Competitive Insights
Strategic Activities by Market Players to Drive Competition
The cell & gene therapy bioanalytical testing services market is fragmented and is anticipated to witness competition due to the presence of several players. The rising efforts taken by the key market players across the world in the form of investments, acquisitions, collaborations, and partnership activities are widening the expansion of global cell and gene therapy bioanalytical testing services.
Major Players Operating in Global Cell & Gene Therapy Bioanalytical Testing Services Market
- BioAgilytix Labs
- Charles River Laboratories
- Intertek Group Plc.
- IQVIA, Inc.
- KCAS Bioanalytical Services
- Laboratory Corporation of America Holdings
- Pharmaron
- Pharmaceutical Product Development, Inc.
- Prolytix
- SGS SA
- Syneos Health
Cell & Gene Therapy Bioanalytical Testing Services Recent Developments in Industry
- May 2026: Merck signed a five-year agreement with Genetix Biotherapeutics to provide analytical and biosafety release testing services for its FDA-approved gene therapies. (Source: merckgroup.com)
Future Outlook
The cell & gene therapy bioanalytical testing services market is expected to experience robust growth in the coming years. The pipeline of advanced therapies continues to expand from early-stage research to commercial production. There are rising investments in cell and gene therapy development and increasing demand for personalized medicine. This will reinforce the demand for bioanalytical testing tailored to specific needs. There are continuous advancements in analytical technologies, automation, next-generation sequencing, and AI-driven analytics. They will increase the efficacy and efficiency of such testing. In addition, increased demands for compliance with stringent regulations worldwide and the use of contract research organizations for testing services will drive continued growth in this market.
Report Coverage
The cell & gene therapy bioanalytical testing services market report emphasizes key regions across the globe to provide a better understanding of the product to the users. Also, the report provides market insights into recent developments and trends and analyzes the technologies that are gaining traction across the world. Furthermore, the report covers an in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides a detailed analysis of the market while focusing on various key aspects such as competitive analysis, test type, product type, stage of development, indication, and their futuristic growth opportunities.
Cell & Gene Therapy Bioanalytical Testing Services Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 579.30 million |
| Market Size Value in 2026 | USD 620.75 million |
| Revenue Forecast in 2034 | USD 1091.86 million |
| CAGR | 7.30% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD million and CAGR from 2026 to 2034 |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Cell & Gene Therapy Bioanalytical Testing Services Market FAQ's
The global cell & gene therapy bioanalytical testing services market size was valued at USD 579.30 million in 2025 and is projected to grow to USD 1091.86 million by 2034.
The global market is projected to grow at a CAGR of 7.30% during the forecast period
Asia Pacific had the largest share in the global market due to the rising prevalence of chronic health conditions.
The key players in the market BioAgilytix Labs, Charles River Laboratories, Intertek Group, IQVIA, KCAS Bioanalytical Services, and Pharmaron.
The cell therapy category dominated the market in 2025 due to rising development of cell therapies is positively impacting the demand for bioanalytical testing services.
The bioavailability and bioequivalence category had the fastest share due to the rising drug development activities.
Cell and gene therapy bioanalytical testing services are adopted to evaluate the safety, efficacy, potency, pharmacokinetics, and quality of advanced therapies. They are used across preclinical studies, clinical trials, and commercialization.
Testing provides essential safety, efficacy, biodistribution, and immunogenicity data that are needed for regulatory purposes, optimizing the product, and developing the gene therapy clinically.
There are several types of tests such as flow cytometry, potency assay, biomarker testing, immunogenicity testing, and pharmacokinetic study. The other types of tests include biodistribution study and molecular characterization.
Regulatory agencies require validated testing for identity, purity, potency, safety, biodistribution, immunogenicity, vector shedding, and analytical method validation before the product is approved.
Download Sample Report of Cell & Gene Therapy Bioanalytical Testing Services Market
Please fill out the form to request a customized copy of the research report.
